{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:57:45Z","timestamp":1791230265906,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic breast cancer remains a leading cause of cancer-related mortality in women, often driven by molecular pathways that promote invasion and immune evasion. MicroRNA-200c (miR-200c) is a known tumor suppressor that inhibits epithelial-mesenchymal transition (EMT), while FOXP3, a transcription factor typically associated with regulatory T cells, is aberrantly expressed in breast cancer cells and may contribute to tumor progression. This study investigates whether targeting the miR-200c\/FOXP3 axis can suppress metastasis in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Metastatic (MDA-MB-361, MDA-MB-468) and non-metastatic (MCF-7) breast cancer cell lines were transfected with miR-200c mimic or inhibitor. Cell proliferation, apoptosis, and invasion were assessed using MTT, Annexin V\/PI staining, and transwell assays. FOXP3 mRNA and protein levels were quantified using qRT-PCR and immunohistochemistry. A metastatic mouse model was established via intracardiac injection of tumor cells, followed by treatment with miR-200c mimic, inhibitor, or Cisplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MiR-200c overexpression significantly suppressed proliferation and invasion and enhanced apoptosis in metastatic cells. FOXP3 mRNA and protein expression were downregulated in mimic-treated cells and tissues, while miR-200c inhibition led to increased FOXP3 expression. In vivo, miR-200c mimic treatment reduced tumor burden and metastatic infiltration in the brain and lungs. A strong inverse correlation between miR-200c and FOXP3 was observed (\n                      <jats:italic>r<\/jats:italic>\n                      = \u2212\u20090.82,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MiR-200c restoration inhibits FOXP3 and suppresses metastatic progression in breast cancer. Targeting the miR-200c\/FOXP3 axis presents a novel and promising therapeutic approach for advanced breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15574-6","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:44:34Z","timestamp":1771047874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-4674","authenticated-orcid":false,"given":"Nashwa","family":"El-Khazragy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alsolami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa N. M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"17","key":"15574_CR1","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","volume":"13","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A. Breast Cancer-Epidemiology, risk Factors, Classification, prognostic Markers, and current treatment Strategies-An updated review. Cancers. 2021;13(17):4287. https:\/\/doi.org\/10.3390\/cancers13174287.","journal-title":"Cancers"},{"issue":"1","key":"15574_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","volume":"3","author":"KS Johnson","year":"2020","unstructured":"Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: A review for breast radiologists. J Breast Imaging. 2020;3(1):12\u201324. https:\/\/doi.org\/10.1093\/jbi\/wbaa110.","journal-title":"J Breast Imaging"},{"key":"15574_CR3","doi-asserted-by":"publisher","unstructured":"Al-thoubaity FK. Molecular classification of breast cancer: a retrospective cohort study. Annals Med Surg. 2020;49:44\u2009\u2013\u20098.. https:\/\/doi.org\/10.1016\/j.amsu.2019.11.021.","DOI":"10.1016\/j.amsu.2019.11.021"},{"issue":"3","key":"15574_CR4","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.clbc.2022.12.010","volume":"23","author":"N El-Khazragy","year":"2022","unstructured":"El-Khazragy N, Gaballah A, Bakkar A, Hemida EHA, Samir N, Tarek M, et al. PTEN rs701848 polymorphism is associated with trastuzumab resistance in HER2-positive metastatic breast cancer and predicts Progression-free survival. Clin Breast Cancer. 2022;23(3):e131\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2022.12.010.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"15574_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S-c. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"15574_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng L-W, Ding Y, Chen Y-F, Cai Y-W, Wang L-P, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Therapy. 2025;10(1):49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4.","journal-title":"Signal Transduct Target Therapy"},{"key":"15574_CR7","doi-asserted-by":"publisher","unstructured":"Sirek T, Sirek A, Zmarz\u0142y N, Op\u0142awski M, Kr\u00f3l-Jatr\u0119ga K, Boro\u0144 D, et al. Impact of MiRNAs on Wnt-related gene activity in breast cancer. Sci Rep. 15;1(16211). https:\/\/doi.org\/10.1038\/s41598-025-00343-5.","DOI":"10.1038\/s41598-025-00343-5"},{"issue":"4","key":"15574_CR8","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.62347\/pngt6996","volume":"15","author":"E Ababneh","year":"2025","unstructured":"Ababneh E, Velez S, Zhao J. Immune evasion and resistance in breast cancer. Am J Cancer Res. 2025;15(4):1517\u201339. https:\/\/doi.org\/10.62347\/pngt6996.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"15574_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3892\/mco.2020.2193","volume":"14","author":"JY Jang","year":"2021","unstructured":"Jang JY, Kim YS, Kang KN, Kim KH, Park YJ, Kim CW. Multiple MicroRNAs as biomarkers for early breast cancer diagnosis. Mol Clin Oncol. 2021;14(2):31. https:\/\/doi.org\/10.3892\/mco.2020.2193.","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"15574_CR10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/cancers12071827","volume":"12","author":"GL Wong","year":"2020","unstructured":"Wong GL, Abu Jalboush S, Lo HW. Exosomal MicroRNAs and organotropism in breast cancer metastasis. Cancers. 2020;12(7):1827. https:\/\/doi.org\/10.3390\/cancers12071827.","journal-title":"Cancers"},{"issue":"16","key":"15574_CR11","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.3390\/ijms23169371","volume":"23","author":"O Baldasici","year":"2022","unstructured":"Baldasici O, Pileczki V, Cruceriu D, Gavrilas LI, Tudoran O, Balacescu L, et al. Breast Cancer-Delivered Exosomal MiRNA as liquid biopsy biomarkers for metastasis prediction: A focus on translational research with clinical applicability. Int J Mol Sci. 2022;23(16):9371. https:\/\/doi.org\/10.3390\/ijms23169371.","journal-title":"Int J Mol Sci"},{"key":"15574_CR12","doi-asserted-by":"publisher","unstructured":"Sirek T, Sirek A, Borawski P, Zmarz\u0142y N, Su\u0142kowska J, Kr\u00f3l-Jatr\u0119ga K, et al. MiRNAs in signal transduction of SMAD proteins in breast cancer. Int J Mol Sci. 2024;25(18). https:\/\/doi.org\/10.3390\/ijms251810088.","DOI":"10.3390\/ijms251810088"},{"key":"15574_CR13","doi-asserted-by":"publisher","first-page":"114243","DOI":"10.1016\/j.ab.2021.114243","volume":"626","author":"B Wen","year":"2021","unstructured":"Wen B, Zhu R, Jin H, Zhao K. Differential expression and role of miR-200 family in multiple tumors. Anal Biochem. 2021;626:114243. https:\/\/doi.org\/10.1016\/j.ab.2021.114243.","journal-title":"Anal Biochem"},{"key":"15574_CR14","doi-asserted-by":"publisher","first-page":"865816","DOI":"10.1155\/2015\/865816","volume":"2015","author":"A Zaravinos","year":"2015","unstructured":"Zaravinos A. The regulatory role of MicroRNAs in EMT and cancer. J Oncol. 2015;2015:865816. https:\/\/doi.org\/10.1155\/2015\/865816.","journal-title":"J Oncol"},{"issue":"1","key":"15574_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13058-017-0858-x","volume":"19","author":"G Zhang","year":"2017","unstructured":"Zhang G, Zhang W, Li B, Stringer-Reasor E, Chu C, Sun L, et al. MicroRNA-200c and microRNA-141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer. Breast Cancer Research: BCR. 2017;19(1):73. https:\/\/doi.org\/10.1186\/s13058-017-0858-x.","journal-title":"Breast Cancer Research: BCR"},{"issue":"12","key":"15574_CR16","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1172\/jci75695","volume":"124","author":"MT Le","year":"2014","unstructured":"Le MT, Hamar P, Guo C, Basar E, Perdig\u00e3o-Henriques R, Balaj L, et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Investig. 2014;124(12):5109\u201328. https:\/\/doi.org\/10.1172\/jci75695.","journal-title":"J Clin Investig"},{"issue":"17","key":"15574_CR17","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.3390\/ijms23179535","volume":"23","author":"C Fischer","year":"2022","unstructured":"Fischer C, Turchinovich A, Feisst M, Riedel F, Ha\u00dfdenteufel K, Scharli P, et al. Circulating miR-200 family and CTCs in metastatic breast cancer before, during, and after a new line of systemic treatment. Int J Mol Sci. 2022;23(17):9535. https:\/\/doi.org\/10.3390\/ijms23179535.","journal-title":"Int J Mol Sci"},{"key":"15574_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.biopha.2018.07.042","volume":"106","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Xing T, Chen Y, Xiao J. Exosome-mediated miR-200b promotes colorectal cancer proliferation upon TGF-\u03b21 exposure. Biomed Pharmacother. 2018;106:1135\u201343. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.042.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"15574_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1476-4598-13-166","volume":"13","author":"J Li","year":"2014","unstructured":"Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F, et al. miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. Mol Cancer. 2014;13(1):166. https:\/\/doi.org\/10.1186\/1476-4598-13-166.","journal-title":"Mol Cancer"},{"issue":"8","key":"15574_CR20","doi-asserted-by":"publisher","first-page":"16833","DOI":"10.3390\/ijms160816833","volume":"16","author":"GG Muralidhar","year":"2015","unstructured":"Muralidhar GG, Barbolina MV. The miR-200 family: versatile players in epithelial ovarian cancer. Int J Mol Sci. 2015;16(8):16833\u201347. https:\/\/doi.org\/10.3390\/ijms160816833.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"15574_CR21","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.3390\/cancers13235874","volume":"13","author":"I Cavallari","year":"2021","unstructured":"Cavallari I, Ciccarese F, Sharova E, Urso L, Raimondi V, Silic-Benussi M, et al. The miR-200 family of micrornas: fine tuners of Epithelial-Mesenchymal transition and Circulating cancer biomarkers. Cancers. 2021;13(23):5874. https:\/\/doi.org\/10.3390\/cancers13235874.","journal-title":"Cancers"},{"issue":"3","key":"15574_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00404-022-06442-2","volume":"306","author":"C Fischer","year":"2022","unstructured":"Fischer C, Deutsch TM, Feisst M, Rippinger N, Riedel F, Hartkopf AD, et al. Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer. Arch Gynecol Obstet. 2022;306(3):875\u201385. https:\/\/doi.org\/10.1007\/s00404-022-06442-2.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"15574_CR23","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3892\/ol.2019.10753","volume":"18","author":"JV Carter","year":"2019","unstructured":"Carter JV, O\u2019Brien SJ, Burton JF, Oxford BG, Stephen V, Hallion J, et al. The microRNA-200 family acts as an oncogene in colorectal cancer by inhibiting the tumor suppressor RASSF2. Oncol Lett. 2019;18(4):3994\u20134007. https:\/\/doi.org\/10.3892\/ol.2019.10753.","journal-title":"Oncol Lett"},{"issue":"32","key":"15574_CR24","doi-asserted-by":"publisher","first-page":"e11505","DOI":"10.1097\/md.0000000000011505","volume":"97","author":"M Shi","year":"2018","unstructured":"Shi M, Mu Y, Zhang H, Liu M, Wan J, Qin X, et al. MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. Med (Baltim). 2018;97(32):e11505. https:\/\/doi.org\/10.1097\/md.0000000000011505.","journal-title":"Med (Baltim)"},{"issue":"12","key":"15574_CR25","doi-asserted-by":"publisher","first-page":"e83991","DOI":"10.1371\/journal.pone.0083991","volume":"8","author":"LV Williams","year":"2013","unstructured":"Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS ONE. 2013;8(12):e83991. https:\/\/doi.org\/10.1371\/journal.pone.0083991.","journal-title":"PLoS ONE"},{"key":"15574_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1479-5876-10-186","volume":"10","author":"M Valladares-Ayerbes","year":"2012","unstructured":"Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-D\u00edaz P, Lorenzo-Pati\u00f1o MJ, Haz M, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Translational Med. 2012;10:186. https:\/\/doi.org\/10.1186\/1479-5876-10-186.","journal-title":"J Translational Med"},{"issue":"6","key":"15574_CR27","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3892\/mco.2016.842","volume":"4","author":"JY Zhang","year":"2016","unstructured":"Zhang JY, Wang YM, Song LB, Chen C, Wang YC, Song NH. Prognostic significance of microRNA\u2013200c in various types of cancer: an updated meta\u2013analysis of 34 studies. Mol Clin Oncol. 2016;4(6):933\u201341. https:\/\/doi.org\/10.3892\/mco.2016.842.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"15574_CR28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.cell.2009.07.011","volume":"138","author":"Y Shimono","year":"2009","unstructured":"Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592\u2013603. https:\/\/doi.org\/10.1016\/j.cell.2009.07.011.","journal-title":"Cell"},{"issue":"5","key":"15574_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.10.010","volume":"53","author":"J van der Veeken","year":"2020","unstructured":"van der Veeken J, Glasner A, Zhong Y, Hu W, Wang Z-M, Bou-Puerto R, et al. The transcription factor Foxp3 shapes regulatory T cell identity by tuning the activity of <\u2009em\u2009>\u2009trans-Acting intermediaries. Immunity. 2020;53(5):971\u201384.e5 https:\/\/doi.org\/10.1016\/j.immuni.2020.10.010.","journal-title":"Immunity"},{"key":"15574_CR30","doi-asserted-by":"publisher","unstructured":"Jia H, Qi H, Gong Z, Yang S, Ren J, Liu Y et al. The expression of FOXP3 and its role in human cancers. Biochimica et biophysica acta (BBA) - Reviews on cancer. 2019;1871(1):170\u20138. https:\/\/doi.org\/10.1016\/j.bbcan.2018.12.004.","DOI":"10.1016\/j.bbcan.2018.12.004"},{"issue":"9","key":"15574_CR31","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/v15091813","volume":"15","author":"AJ Nicola Candia","year":"2023","unstructured":"Nicola Candia AJ, Garcia Fallit M, Pe\u00f1a Agudelo JA, P\u00e9rez K\u00fcper M, Gonzalez N, Moreno Ayala MA, et al. Targeting FOXP3 Tumor-Intrinsic effects using adenoviral vectors in experimental breast cancer. Viruses. 2023;15(9):1813. https:\/\/doi.org\/10.3390\/v15091813.","journal-title":"Viruses"},{"issue":"1","key":"15574_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/cre2.477","volume":"8","author":"T Hayashi","year":"2022","unstructured":"Hayashi T, Yoshikawa K, Suzuki S, Gosho M, Ueda R, Kazaoka Y. Tumor-infiltrating FoxP3\u2009+\u2009T cells are associated with poor prognosis in oral squamous cell carcinoma. Clin Experimental Dent Res. 2022;8(1):152\u20139. https:\/\/doi.org\/10.1002\/cre2.477.","journal-title":"Clin Experimental Dent Res"},{"key":"15574_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bcp.2017.11.008","volume":"147","author":"X Bian","year":"2018","unstructured":"Bian X, Liang Z, Feng A, Salgado E, Shim H. HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL. Biochem Pharmacol. 2018;147:30\u20137. https:\/\/doi.org\/10.1016\/j.bcp.2017.11.008.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"15574_CR34","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3390\/ijms26020710","volume":"26","author":"H Guo","year":"2025","unstructured":"Guo H, Zhang N, Huang T, Shen N. MicroRNA-200c in cancer Generation, Invasion, and metastasis. Int J Mol Sci. 2025;26(2):710. https:\/\/doi.org\/10.3390\/ijms26020710.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"15574_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12967-025-06422-5","volume":"23","author":"Y Xie","year":"2025","unstructured":"Xie Y, Wang X, Wang W, Pu N, Liu L. Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges. J Translational Med. 2025;23(1):386. https:\/\/doi.org\/10.1186\/s12967-025-06422-5.","journal-title":"J Translational Med"},{"issue":"11","key":"15574_CR36","doi-asserted-by":"publisher","first-page":"e50469","DOI":"10.1371\/journal.pone.0050469","volume":"7","author":"F Kopp","year":"2012","unstructured":"Kopp F, Oak PS, Wagner E, Roidl A. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS ONE. 2012;7(11):e50469. https:\/\/doi.org\/10.1371\/journal.pone.0050469.","journal-title":"PLoS ONE"},{"key":"15574_CR37","doi-asserted-by":"publisher","first-page":"982986","DOI":"10.3389\/fimmu.2022.982986","volume":"13","author":"Y Qiu","year":"2022","unstructured":"Qiu Y, Ke S, Chen J, Qin Z, Zhang W, Yuan Y, et al. FOXP3\u2009+\u2009regulatory T cells and the immune escape in solid tumours. Front Immunol. 2022;13:982986. https:\/\/doi.org\/10.3389\/fimmu.2022.982986.","journal-title":"Front Immunol"},{"issue":"32","key":"15574_CR38","doi-asserted-by":"publisher","first-page":"38323","DOI":"10.1021\/acsami.3c07541","volume":"15","author":"I Garrido-Cano","year":"2023","unstructured":"Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez JF, Candela-Noguera V, Lluch A, et al. Delivery of miR-200c-3p using Tumor-Targeted mesoporous silica nanopar ticles for breast cancer therapy. ACS Appl Mater Interfaces. 2023;15(32):38323\u201334. https:\/\/doi.org\/10.1021\/acsami.3c07541.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"15574_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19336918.2019.1710015","volume":"14","author":"P Li","year":"2020","unstructured":"Li P, Butcher NJ, Minchin RF. Effect of arylamine N-acetyltransferase 1 on morphology, adhesion, migration, and invasion of MDA-MB-231 cells: role of matrix metalloproteinases and integrin \u03b1V. Cell Adhes Migr. 2020;14(1):1\u201311. https:\/\/doi.org\/10.1080\/19336918.2019.1710015.","journal-title":"Cell Adhes Migr"},{"issue":"5","key":"15574_CR40","doi-asserted-by":"publisher","first-page":"0173","DOI":"10.3390\/metabo10050173","volume":"10","author":"W Wojtowicz","year":"2020","unstructured":"Wojtowicz W, Wr\u00f3bel A, Pyziak K, Tarkowski R, Balcerzak A, B\u0119benek M, et al. Evaluation of MDA-MB-468 cell culture media analysis in predicting Triple-Negative breast cancer patient Sera metabolic profiles. Metabolites. 2020;10(5):0173. https:\/\/doi.org\/10.3390\/metabo10050173.","journal-title":"Metabolites"},{"issue":"8","key":"15574_CR41","doi-asserted-by":"publisher","first-page":"e0135426","DOI":"10.1371\/journal.pone.0135426","volume":"10","author":"MM Vantangoli","year":"2015","unstructured":"Vantangoli MM, Madnick SJ, Huse SM, Weston P, Boekelheide K. MCF-7 human breast cancer cells form differentiated microtissues in Scaffold-Free hydrogels. PLoS ONE. 2015;10(8):e0135426. https:\/\/doi.org\/10.1371\/journal.pone.0135426.","journal-title":"PLoS ONE"},{"issue":"16","key":"15574_CR42","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.7150\/jca.18457","volume":"8","author":"X Dai","year":"2017","unstructured":"Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8(16):3131\u201341. https:\/\/doi.org\/10.7150\/jca.18457.","journal-title":"J Cancer"},{"issue":"33","key":"15574_CR43","doi-asserted-by":"publisher","first-page":"34968","DOI":"10.18632\/oncotarget.5198","volume":"6","author":"C Song","year":"2015","unstructured":"Song C, Liu LZ, Pei XQ, Liu X, Yang L, Ye F, et al. miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget. 2015;6(33):34968\u201378. https:\/\/doi.org\/10.18632\/oncotarget.5198.","journal-title":"Oncotarget"},{"issue":"4","key":"15574_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/diseases6040085","volume":"6","author":"JL Gordon","year":"2018","unstructured":"Gordon JL, Brown MA, Reynolds MM. Cell-Based methods for determination of efficacy for candidate therapeutics in the clinical management of cancer. Diseases. 2018;6(4):85. https:\/\/doi.org\/10.3390\/diseases6040085.","journal-title":"Diseases"},{"issue":"8","key":"15574_CR45","first-page":"3201","volume":"33","author":"A Bundscherer","year":"2013","unstructured":"Bundscherer A, Malsy M, Lange R, Hofmann P, Metterlein T, Graf BM, et al. Cell harvesting method influences results of apoptosis analysis by Annexin V staining. Anticancer Res. 2013;33(8):3201\u20134.","journal-title":"Anticancer Res"},{"issue":"6","key":"15574_CR46","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.21769\/bioprotoc.374","volume":"3","author":"I Lakshmanan","year":"2013","unstructured":"Lakshmanan I, Batra SK. Protocol for apoptosis assay by flow cytometry using Annexin V staining method. Bio Protoc. 2013;3(6):e374. https:\/\/doi.org\/10.21769\/bioprotoc.374.","journal-title":"Bio Protoc"},{"key":"15574_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fcell.2019.00107","volume":"7","author":"J Pijuan","year":"2019","unstructured":"Pijuan J, Barcel\u00f3 C, Moreno DF, Maiques O, Sis\u00f3 P, Marti RM, et al. In vitro cell Migration, Invasion, and adhesion assays: from cell imaging to data analysis. Front Cell Dev Biol. 2019;7:107. https:\/\/doi.org\/10.3389\/fcell.2019.00107.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"15574_CR48","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1002\/cpim.78","volume":"126","author":"N Zhang","year":"2019","unstructured":"Zhang N, Hu G, Myers TG, Williamson PR. Protocols for the analysis of MicroRNA Expression, Biogenesis, and function in immune cells. Curr Protoc Immunol. 2019;126(1):e78. https:\/\/doi.org\/10.1002\/cpim.78.","journal-title":"Curr Protoc Immunol"},{"issue":"10","key":"15574_CR49","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s41419-018-1094-8","volume":"9","author":"N Pillar","year":"2018","unstructured":"Pillar N, Polsky AL, Weissglas-Volkov D, Shomron N. Comparison of breast cancer metastasis models reveals a possible mechanism of tumor aggressiveness. Cell Death Dis. 2018;9(10):1040. https:\/\/doi.org\/10.1038\/s41419-018-1094-8.","journal-title":"Cell Death Dis"},{"issue":"10","key":"15574_CR50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41389-020-00283-x","volume":"9","author":"Z Gong","year":"2020","unstructured":"Gong Z, Jia H, Yu J, Liu Y, Ren J, Yang S, et al. Nuclear FOXP3 inhibits tumor growth and induced apoptosis in hepatocellular carcinoma by targeting c-Myc. Oncogenesis. 2020;9(10):97. https:\/\/doi.org\/10.1038\/s41389-020-00283-x.","journal-title":"Oncogenesis"},{"issue":"3","key":"15574_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/curroncol32030143","volume":"32","author":"T Moura","year":"2025","unstructured":"Moura T, Laranjeira P, Caramelo O, Gil AM, Paiva A. Breast cancer and tumor microenvironment: the crucial role of immune cells. Curr Oncol. 2025;32(3):143. https:\/\/doi.org\/10.3390\/curroncol32030143.","journal-title":"Curr Oncol"},{"issue":"3","key":"15574_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.14715\/cmb\/2024.70.3.3","volume":"70","author":"S Ezzat","year":"2024","unstructured":"Ezzat S, Magda IM, Manal Basyouni A, Sara Elsayed A, Nesma Hussein Abdel H, Nashwa E-K, et al. The tumor suppressor effect of MiRNA 200-c-3p on A549 non-small cell lung cancer cell line is associated with down-regulation of programmed cell death ligand 1; an immune-check point mechanism. Cellular and molecular biology. France). 2024;70(3):13\u201321. https:\/\/doi.org\/10.14715\/cmb\/2024.70.3.3. (Noisy-le-Grand.","journal-title":"France)"},{"key":"15574_CR53","doi-asserted-by":"publisher","first-page":"104753","DOI":"10.1016\/j.yexmp.2022.104753","volume":"125","author":"S Safaei","year":"2022","unstructured":"Safaei S, Amini M, Najjary S, Mokhtarzadeh A, Bolandi N, Saeedi H, et al. miR-200c increases the sensitivity of breast cancer cells to doxorubicin through downregulating MDR1 gene. Exp Mol Pathol. 2022;125:104753. https:\/\/doi.org\/10.1016\/j.yexmp.2022.104753.","journal-title":"Exp Mol Pathol"},{"issue":"6","key":"15574_CR54","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.3892\/or.2018.6735","volume":"40","author":"J Chen","year":"2018","unstructured":"Chen J, Tian W, He H, Chen F, Huang J, Wang X, et al. Downregulation of miR\u2013200c\u20133p contributes to the resistance of breast cancer cells to Paclitaxel by targeting SOX2. Oncol Rep. 2018;40(6):3821\u20139. https:\/\/doi.org\/10.3892\/or.2018.6735.","journal-title":"Oncol Rep"},{"key":"15574_CR55","doi-asserted-by":"publisher","first-page":"965231","DOI":"10.3389\/fonc.2022.965231","volume":"12","author":"K Klicka","year":"2022","unstructured":"Klicka K, Grzywa TM, Mielniczuk A, Klinke A, W\u0142odarski PK. The role of miR-200 family in the regulation of hallmarks of cancer. Front Oncol. 2022;12:965231. https:\/\/doi.org\/10.3389\/fonc.2022.965231.","journal-title":"Front Oncol"},{"issue":"6","key":"15574_CR56","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.molcel.2010.05.018","volume":"38","author":"R Schickel","year":"2010","unstructured":"Schickel R, Park S-M, Murmann AE, Peter ME. mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010;38(6):908\u201315. https:\/\/doi.org\/10.1016\/j.molcel.2010.05.018.","journal-title":"Mol Cell"},{"issue":"2","key":"15574_CR57","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/genes12020267","volume":"12","author":"B Mansoori","year":"2021","unstructured":"Mansoori B, Silvestris N, Mohammadi A, Khaze V, Baghbani E, Mokhtarzadeh A, et al. miR-34a and miR-200c have an additive Tumor-Suppressive effect on breast cancer cells and patient prognosis. Genes (Basel). 2021;12(2):267. https:\/\/doi.org\/10.3390\/genes12020267.","journal-title":"Genes (Basel)"},{"key":"15574_CR58","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12885-015-1238-5","volume":"15","author":"S Antol\u00edn","year":"2015","unstructured":"Antol\u00edn S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Pati\u00f1o MJ, Haz-Conde M, et al. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 2015;15:297. https:\/\/doi.org\/10.1186\/s12885-015-1238-5.","journal-title":"BMC Cancer"},{"issue":"10","key":"15574_CR59","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12094-015-1303-1","volume":"17","author":"M Zuberi","year":"2015","unstructured":"Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, et al. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clin Transl Oncol. 2015;17(10):779\u201387. https:\/\/doi.org\/10.1007\/s12094-015-1303-1.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"15574_CR60","doi-asserted-by":"publisher","first-page":"e7181","DOI":"10.1371\/journal.pone.0007181","volume":"4","author":"DM Dykxhoorn","year":"2009","unstructured":"Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE. 2009;4(9):e7181. https:\/\/doi.org\/10.1371\/journal.pone.0007181.","journal-title":"PLoS ONE"},{"issue":"31","key":"15574_CR61","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1038\/onc.2013.370","volume":"33","author":"X Li","year":"2014","unstructured":"Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, et al. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene. 2014;33(31):4077\u201388. https:\/\/doi.org\/10.1038\/onc.2013.370.","journal-title":"Oncogene"},{"key":"15574_CR62","doi-asserted-by":"publisher","first-page":"102097","DOI":"10.1016\/j.canep.2022.102097","volume":"77","author":"T Thi Chung Duong","year":"2022","unstructured":"Thi Chung Duong T, Nguyen THN, Thi Ngoc Nguyen T, Huynh LH, Ngo HP, Thi Nguyen H. Diagnostic and prognostic value of miR-200 family in breast cancer: A meta-analysis and systematic review. Cancer Epidemiol. 2022;77:102097. https:\/\/doi.org\/10.1016\/j.canep.2022.102097.","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"15574_CR63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.22074\/cellj.2020.6406","volume":"21","author":"M Rahimi","year":"2020","unstructured":"Rahimi M, Sharifi-Zarchi A, Zarghami N, Geranpayeh L, Ebrahimi M, Alizadeh E. Down-Regulation of miR-200c and Up-Regulation of miR-30c target both stemness and metastasis genes in breast cancer. Cell J. 2020;21(4):467\u201378. https:\/\/doi.org\/10.22074\/cellj.2020.6406.","journal-title":"Cell J"},{"issue":"19","key":"15574_CR64","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.3390\/molecules27196706","volume":"27","author":"B Ma","year":"2022","unstructured":"Ma B, Miao W, Xiao J, Chen X, Xu J, Li Y. The role of FOXP3 on tumor metastasis and its interaction with traditional Chinese medicine. Molecules. 2022;27(19):6706. https:\/\/doi.org\/10.3390\/molecules27196706.","journal-title":"Molecules"},{"key":"15574_CR65","doi-asserted-by":"publisher","first-page":"216838","DOI":"10.1016\/j.canlet.2024.216838","volume":"590","author":"R Gong","year":"2024","unstructured":"Gong R, Wang J, Xing Y, Wang J, Chen X, Lei K, et al. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma. Cancer Lett. 2024;590:216838. https:\/\/doi.org\/10.1016\/j.canlet.2024.216838.","journal-title":"Cancer Lett"},{"key":"15574_CR66","doi-asserted-by":"publisher","first-page":"656190","DOI":"10.3389\/fonc.2021.656190","volume":"11","author":"C Liu","year":"2021","unstructured":"Liu C, Han J, Li X, Huang T, Gao Y, Wang B, et al. FOXP3 inhibits the metastasis of breast cancer by downregulating the expression of MTA1. Front Oncol. 2021;11:656190. https:\/\/doi.org\/10.3389\/fonc.2021.656190.","journal-title":"Front Oncol"},{"issue":"3","key":"15574_CR67","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cam4.1024","volume":"6","author":"P Li","year":"2017","unstructured":"Li P, Xu T, Zhou X, Liao L, Pang G, Luo W, et al. Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: involvement of ANP32E targeting. Cancer Med. 2017;6(3):662\u201372. https:\/\/doi.org\/10.1002\/cam4.1024.","journal-title":"Cancer Med"},{"key":"15574_CR68","doi-asserted-by":"publisher","first-page":"153303382412922","DOI":"10.1177\/15330338241292226","volume":"23","author":"MS Othman","year":"2024","unstructured":"Othman MS, Elabbasy MT, Aref AM, Altaleb AA, Mohammed MH, Soliman DAM, et al. The MiR-200c\/FOXP3 network: A promising biomarker for predicting trastuzumab response in HER2-Positive breast cancer. Technol Cancer Res Treat. 2024;23:15330338241292226. https:\/\/doi.org\/10.1177\/15330338241292226.","journal-title":"Technol Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15574-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15574-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15574-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:42:40Z","timestamp":1771850560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15574-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15574"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15574-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in compliance with institutional ethical guidelines and approved by the Institutional Animal Care and Use Committee (IACUC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"297"}}